Equities

SKAN Group AG

SKAN Group AG

Actions
  • Price (CHF)75.80
  • Today's Change-0.50 / -0.66%
  • Shares traded3.59k
  • 1 Year change-5.01%
  • Beta--
Data delayed at least 15 minutes, as of Jul 23 2024 14:33 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SKAN Group AG, former BV Holding AG, is a Switzerland-based holding company of an equity investment group, engaged in the participation in enterprises in Switzerland. It concentrates on companies from the industry, micro and medical technology, processing and material technology, information technology and related services. Target enterprises are those being in special situations, such as management buy-out and buy-in, changes in shareholders’ structure, succession financing, as well as coming through growth or expansion phase. The Company acts as an entrepreneurial partner in the long term. Operational activities are delegated to the independent advisor BV Partners AG. BV Holding AG and BV Partners AG form the BVgroup. As of December 31, 2011, its investment portfolio included nine companies: Covalys BioSciences AG, E2E Technologies Ltd., Lonstroff Holding AG, Piexon AG, POLYDATA AG, SKAN Holding AG, Sphinx Werkzeuge AG, Ypsomed Holding AG and Ziemer Group AG.

  • Revenue in CHF (TTM)320.02m
  • Net income in CHF26.31m
  • Incorporated2001
  • Employees1.39k
  • Location
    SKAN Group AGKreuzstrasse 5ALLSCHWIL 4123SwitzerlandCHE
  • Phone+41 432683232
  • Fax+41 313801859
  • Websitehttps://skan.com/de/home/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arjo AB (publ)931.76m44.49m910.53m6.94k21.931.487.090.97721.971.9741.2129.200.69574.406.511,651,221.003.313.554.515.5543.6844.014.765.410.66574.010.412343.0110.035.976.9010.15-8.8910.35
Medartis Holding AG212.01m619.00k969.66m829.001,463.123.4644.854.570.04880.048817.3320.630.62590.6435.27255,737.000.1830.19190.20950.215379.0482.330.29240.35421.591.460.16550.0015.9611.81110.70-31.825.37--
Oxford Nanopore Technologies PLC195.24m-177.80m1.11bn1.24k--1.48--5.70-0.1851-0.18510.20350.74930.2120.83692.73137,050.10-19.30-21.12-21.93-24.6753.3353.90-91.06-81.853.87--0.0608---14.5739.15-69.74--8.92--
GVS SpA411.49m19.90m1.13bn4.39k58.843.3617.872.750.11350.11352.381.990.42011.956.2096,823.302.037.352.5010.8253.9258.744.8412.441.193.870.5709--9.5815.25-43.37-9.9716.08--
Biotage AB172.32m20.75m1.26bn667.0060.894.0135.457.333.123.1225.9347.360.42171.706.573,080,119.005.0810.745.8712.7762.7261.3412.0415.771.148.710.062840.1118.9015.37-8.217.9714.051.30
Xvivo Perfusion AB58.00m10.02m1.41bn152.00136.328.3789.4524.253.953.9522.6964.280.34411.224.484,367,031.005.951.246.451.3374.1673.1417.284.763.27--0.01330.0043.8826.04398.2948.5721.35--
Embla Medical hf716.09m50.68m1.62bn4.00k31.872.4816.822.260.91490.914912.9111.740.55822.206.601,378,933.003.964.064.684.7661.4162.477.096.911.075.810.43253.999.335.0937.34-6.056.50--
SKAN Group AG320.02m26.31m1.75bn1.39k66.8710.3643.535.481.171.1714.237.530.84020.702612.19230,562.007.327.5615.1614.9575.1773.248.729.630.7817.610.035524.0915.55118.7738.5935.49----
Elekta AB (publ)1.50bn107.99m2.07bn4.64k19.922.4010.231.383.403.4047.3728.200.59393.583.013,904,116.004.274.197.607.5137.5639.037.197.370.76443.830.402168.607.415.9838.071.6820.225.92
Medacta Group SA493.91m45.80m2.44bn1.73k53.237.6223.854.942.292.2924.7116.010.79790.87085.92285,494.307.407.899.0910.5768.1070.439.2710.090.90044.800.381717.0116.8513.382.410.69378.32--
Vitrolife AB293.43m-315.35m2.51bn1.12k--2.31--8.57-28.06-28.0626.1196.720.18363.656.163,276,182.00-19.72-4.57-20.43-4.7857.4858.38-107.41-21.892.43-39.300.1379--8.6024.99-1,077.41---7.953.30
Data as of Jul 23 2024. Currency figures normalised to SKAN Group AG's reporting currency: Swiss Franc CHF

Institutional shareholders

21.96%Per cent of shares held by top holders
HolderShares% Held
J. Safra Sarasin Investmentfonds AGas of 31 Dec 2023785.00k3.49%
VV Verm�gensverwaltung AGas of 30 Apr 2024785.00k3.49%
Capital Research & Management Co. (World Investors)as of 30 Jun 2024713.91k3.18%
Z�rcher Kantonalbank (Investment Management)as of 31 May 2024586.76k2.61%
Pictet Asset Management SAas of 31 Mar 2024451.07k2.01%
The Vanguard Group, Inc.as of 04 Jul 2024392.69k1.75%
Threadneedle Asset Management Ltd.as of 30 Apr 2024385.42k1.71%
Vontobel Asset Management AGas of 30 Jun 2024330.26k1.47%
Norges Bank Investment Managementas of 31 Dec 2023262.81k1.17%
Credit Suisse Asset Management (Schweiz) AGas of 28 Jun 2024245.15k1.09%
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.